Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VivescOs feasibility study for reconstruction of intra-oral bone defects
NL-OMON24005Active, not recruiting
- Sponsor
- IsoTis
- Start
- Nov 2000
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of VivescOs in Bone defect, sponsored by IsoTis. Primary endpoint: Safety of VivescOs. Started Nov 2000; status: active, not recruiting.
02
Drugs
VivescOs
03
Conditions
Bone defect
Beyond the preview
Go deeper on NL-OMON24005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24005.